Advertisement
ARCT vs AXON
Which Stock Would AI Choose? Arcturus Therapeutics (ARCT) vs. Axon Enterprise (AXON) Stock Comparison
Key Takeaways
- ARCT is a clinical-stage mRNA (messenger RNA) medicines company whose revenue has contracted sharply as a legacy collaboration wound down, leaving the stock highly sensitive to pipeline milestones.
- AXON is a fast-growing public-safety technology firm converting hardware sales into high-margin software subscriptions, with revenue growing roughly 30–40% in recent quarters.
- The two names sit at opposite ends of the risk spectrum: ARCT is a pre-revenue-stage biotech story, while AXON is a profitable, scaling SaaS (software-as-a-service) business.
- ARCT has displayed sharp, catalyst-driven price swings, whereas AXON offers more consistent but valuation-sensitive relative performance.
- Analyst consensus skews positive on both, but the drivers—clinical data versus recurring revenue and AI adoption—are fundamentally different.
Introduction
Comparing ARCT and AXON is, in many ways, a study in contrasts. One is a small-cap biotechnology company whose valuation hinges on experimental therapies; the other is a mid-cap technology leader monetizing an expanding ecosystem of devices, software, and artificial intelligence. This stock comparison is most relevant to investors weighing growth versus speculation and seeking to understand how relative performance and market positioning diverge across sectors. By examining business models, momentum, risk factors, and sentiment, traders can better assess which profile aligns with their own objectives in the current market environment.
ARCT Overview and Recent Performance
Arcturus Therapeutics Holdings is a messenger RNA medicines company focused on liver and respiratory rare-disease therapeutics, including ARCT-032 for cystic fibrosis and ARCT-810 for ornithine transcarbamylase (OTC) deficiency. In recent quarters, the company's reported revenue has fallen sharply as collaboration income from a prior partner rolled off, with top-line results dropping to single-digit millions and net losses widening.
Recent market activity has been notably volatile. After trading near multi-year lows, the stock staged a pronounced rebound in recent weeks as investors reframed the company's cash runway—management has signaled funding extending toward year-end 2028—and anticipated late-stage clinical decisions. Analysts have largely maintained constructive ratings, with several firms reiterating Buy recommendations and raising price targets. Sentiment has been driven primarily by upcoming data readouts and a potential Phase 3 decision, rather than by current financial results.
AXON Overview and Recent Performance
Axon Enterprise provides public-safety technology, including TASER devices, body-worn cameras, and a cloud-based evidence management and software platform. The company has steadily shifted toward recurring revenue, with its Software and Services segment growing at a roughly 40% pace and annual recurring revenue surpassing $1 billion. Its most recent quarterly results showed total revenue up approximately 39% year over year, supported by strong demand for the TASER 10 and Axon Body 4.
Despite robust top-line growth, recent performance has been uneven at the margin level. Tariff-related cost pressures and a mixed quarterly earnings report briefly pressured the stock, prompting some analysts to trim price targets even while keeping constructive ratings. Over the longer term, shares have delivered substantial gains, with a multi-year total return well above 200%. Current sentiment centers on AI-powered products, expanding backlog, and the pace at which software margins can offset hardware cost inflation.
Trending AI Robots
Tickeron's Trending AI Robots page curates a focused selection of the platform's most promising AI trading bots. While Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, only those best suited to current market conditions earn a place in this featured section. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the specific sets of tickers they follow—ranging from momentum-driven approaches to more measured, trend-following systems. By concentrating on proven, actively monitored bots, the page helps traders cut through the noise and identify tools aligned with prevailing market dynamics. Explore the Trending AI Robots page to see which strategies are currently leading.
Head-to-Head Comparison
The most fundamental contrast between ARCT and AXON lies in their business models. ARCT is a binary, catalyst-dependent biotech with minimal recurring revenue, high cash burn, and a valuation tied to clinical and regulatory outcomes. AXON, by contrast, generates substantial, growing revenue with strong net revenue retention and a multi-billion-dollar contracted backlog, giving it greater visibility into future sales.
Growth drivers also differ sharply. ARCT's upside depends on successful trial data, potential partnerships, and eventual commercialization of its rare-disease pipeline. AXON's growth is propelled by product cycles, AI adoption, and international and federal contract expansion. On momentum, ARCT has experienced rapid, volatile price swings around news flow, while AXON's moves have been steadier but increasingly sensitive to valuation and margin expectations.
Risk profiles are equally divergent. ARCT carries elevated clinical, regulatory, and dilution risk, offset by a potentially substantial reward if its therapies advance. AXON's risks center on government budget cycles, tariff exposure, and regulatory scrutiny of AI-enabled surveillance—concerns that could pressure a premium valuation. Sector exposure reinforces the divide: biotechnology versus public-safety technology.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor AXON as the more consistent candidate in the current environment. AXON demonstrates clearer trend consistency, recurring revenue visibility, and multiple identifiable catalysts tied to AI adoption and contract momentum. ARCT, while carrying meaningful analyst support and potentially larger percentage upside, remains contingent on binary clinical outcomes that introduce greater instability into its price trend. This assessment reflects relative market positioning and probabilistic trend analysis rather than a definitive forecast, and conditions may shift as new data and earnings emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Hold and AXON is a Buy.
Momentum Indicator for ARCT turns negative, indicating new downward trend
ARCT saw its Momentum Indicator move below the 0 level on September 25, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned negative. In 76 of the 83 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
ARCT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARCT crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ARCT entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARCT advanced for three days, in 229 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ARCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.816) is normal, around the industry mean (3.009). P/E Ratio (-3.297) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (23.364) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. ARCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
AXON's RSI Oscillator recovers from oversold territory
The RSI Indicator for AXON moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 23 of the 27 cases the stock moved higher. This puts the odds of a move higher at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for AXON just turned positive on October 06, 2026. Looking at past instances where AXON's MACD turned positive, the stock continued to rise in 29 of 38 cases over the following month. The odds of a continued upward trend are 76%.
Following a +4.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 276 of 371 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. AXON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.681) is normal, around the industry mean (4.871). AXON has a moderately high P/E Ratio (158.964) as compared to the industry average of (16.733). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (2.564). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.330).
ARCT | AXON | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 63 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 33 Fair valued | 92 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 72 | |
SMR RATING 1..100 | 98 | 81 | |
PRICE GROWTH RATING 1..100 | 50 | 64 | |
P/E GROWTH RATING 1..100 | 96 | 47 | |
SEASONALITY SCORE 1..100 | 85 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARCT's Valuation (33) in the Pharmaceuticals Major industry is somewhat better than the same rating for AXON (92) in the Biotechnology industry. This means that ARCT’s stock grew somewhat faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (72) in the Biotechnology industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that AXON’s stock grew similarly to ARCT’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as ARCT (98) in the Pharmaceuticals Major industry. This means that AXON’s stock grew similarly to ARCT’s over the last 12 months.
ARCT's Price Growth Rating (50) in the Pharmaceuticals Major industry is in the same range as AXON (64) in the Biotechnology industry. This means that ARCT’s stock grew similarly to AXON’s over the last 12 months.
AXON's P/E Growth Rating (47) in the Biotechnology industry is somewhat better than the same rating for ARCT (96) in the Pharmaceuticals Major industry. This means that AXON’s stock grew somewhat faster than ARCT’s over the last 12 months.
| ARCT | AXON | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 85% |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 82% |
| Momentum ODDS (%) | 1 day ago 90% | N/A |
| MACD ODDS (%) | N/A | 1 day ago 76% |
| TrendWeek ODDS (%) | 1 day ago 86% | 1 day ago 69% |
| TrendMonth ODDS (%) | 1 day ago 84% | 1 day ago 71% |
| Advances ODDS (%) | 1 day ago 82% | 12 days ago 74% |
| Declines ODDS (%) | 7 days ago 88% | 2 days ago 70% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 79% |
| Aroon ODDS (%) | 1 day ago 87% | 1 day ago 58% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARCT’s FA Score shows that 1 FA rating(s) are green while AXON’s FA Score has 0 green FA rating(s).
- ARCT’s FA Score: 1 green, 4 red.
- AXON’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARCT’s TA Score shows that 3 TA indicator(s) are bullish while AXON’s TA Score has 5 bullish TA indicator(s).
- ARCT’s TA Score: 3 bullish, 5 bearish.
- AXON’s TA Score: 5 bullish, 2 bearish.
Price Growth
ARCT (@Biotechnology) experienced а -8.73% price change this week, while AXON (@Aerospace & Defense) price change was -5.01% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -3.13%. For the same industry, the average monthly price growth was -14.41%, and the average quarterly price growth was -18.78%.
Reported Earning Dates
ARCT is expected to report earnings on Nov 09, 2026.
AXON is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Biotechnology (-0.45% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Aerospace & Defense (-3.13% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
Advertisement
ARCT and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with ALEC. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then ALEC could also see price increases.
| Ticker / NAME | Correlation To ARCT | 1D Price Change % | ||
|---|---|---|---|---|
| ARCT | 100% | +5.37% | ||
| ALEC - ARCT | 60% Loosely correlated | +1.03% | ||
| AXON - ARCT | 49% Loosely correlated | +2.49% | ||
| CRSP - ARCT | 45% Loosely correlated | -0.32% | ||
| BEAM - ARCT | 43% Loosely correlated | +3.06% | ||
| VCYT - ARCT | 42% Loosely correlated | +2.26% | ||
More | ||||